A pilot study of cetuximab and the hedgehog inhibitor IPI-926 in recurrent/metastatic head and neck squamous cell carcinoma-Science-Chemical Encyclopedia-lookchem

A pilot study of cetuximab and the hedgehog inhibitor IPI-926 in recurrent/metastatic head and neck squamous cell carcinoma
Add time:08/24/2019 Source:sciencedirect.com

SummaryBackgroundThis phase 1, dose-finding study determined the safety, maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D), antitumor activity, and molecular correlates of IPI-926, a Hedgehog pathway (HhP) inhibitor, combined with cetuximab in patients with relapsed/metastatic squamous cell carcinoma of the head and neck.

We also recommend Trading Suppliers and Manufacturers of CI 926 (cas 104683-52-5). Pls Click Website Link as below: cas 104683-52-5 suppliers

Prev:Chapter Ten - Atomic Electronic Structure Computations With Hylleraas-CI Wave Functions
Next: ABCB1/MDR1 contributes to the anticancer drug-resistant phenotype of IPH-926 human lobular breast cancer cells)

Click to view details

Health and Chemicalmore >